NCT06922656View on ClinicalTrials.gov

Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

January 15, 2027

Conditions
Type 1 Diabetes
Interventions
DRUG

Dapagliflozin (DAPA)

The hypothesis tested in the original study was whether the addition of pioglitazone in patients with type 1 diabetes mellitus (T1DM) receiving therapy with dapagliflozin would amplify the decrease in HbA1c and prevent the increase in plasma ketone concentration caused by dapagliflozin.

DRUG

Pioglitazone 45 mg

The hypothesis tested in the original study was whether the addition of pioglitazone in patients with type 1 diabetes mellitus (T1DM) receiving therapy with dapagliflozin would amplify the decrease in HbA1c and prevent the increase in plasma ketone concentration caused by dapagliflozin.

DRUG

Placebo

Placebo

Trial Locations (3)

1180

Dasman Diabetes Institute, Kuwait City

Unknown

Hamad Medical Corporation, Doha

Diabetes and Endocrine Treatment Center, Prince Sultan Military Medical City. Kidney & Pancreas Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital & Research Centre, Alfaisal Univeristy, Riyadh, Kingdom of Saudi Arabia, Riyadh

All Listed Sponsors
lead

Dasman Diabetes Institute

OTHER